A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group study.

Abstract

There seems to be no significant advantage for consolidation whole-abdominal RT compared with the continuation of the same chemotherapy in the management of advanced epithelial carcinoma of the ovary, even when no macroscopic residual disease is apparent at second-look surgery.

A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer

“…Comparison of the survival data from our study with that of a matched population of patients with suboptimally debulked, advanced ovarian cancer, all of whom received between five and eight cycles of carboplatin (Lambert et al, 1993(Lambert et al, , 1997, were identical. Therefore, it is plausible that patients in the current study were not disadvantaged by receiving only two cycles of carboplatin.…”

“…Survival in the study population is compared in these figures with 3 7 2 2 0 0 0 0 1 3 1 1 Mucositis 0 0 0 0 1 2 1 1 0 0 0 0 Diarrhoea 1 2 1 1 0 0 0 0 2 5 2 1 Alopecia 0 0 0 0 15 37 22 28 18 47 72 50 Thromboembolic event 2 5 2 2 1 2 2 3 0 0 0 0 Haematological Anaemia 1 2 1 1 2 5 2 3 6 16 6 4 Neutropenia 2 5 0 0 2 5 3 4 31 82 88 61 Neutropenic sepsis 2 5 2 2 2 5 2 3 5 13 8 6 Thrombocytopenia 1 2 1 1 0 0 1 1 4 11 5 that of a matched group of patients from two previous North Thames ovary trials and found to be similar (Lambert et al, 1993;Lambert et al, 1997). In this group, all patients had inoperable disease or measurable disease 42 cm at the end of surgery and received between five and eight cycles of carboplatin.…”

Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation

“…More recently published results have even disclaimed a benefit for WAR in patients with residual disease after intensive chemotherapy and second-look surgery [17,18]. A randomized trial in a small number of patients showed no difference in survival [19]. The fact that only one randomized trial has been published illustrates the difficulties of prospectively planned multimodality treatments.…”

La radiothérapie dans les cancers ovariens a-t-elle encore une place?

“…Valeur de la radiothé rapie abdomino-pelvienne par rapport aux autres traitements de consolidation Les essais randomisé s ont comparé , aprè s laparotomie de contrô le né gative ou avec ré sidus dits « minimes » (infé rieurs à 2 cm), la RAP versus une polychimiothé -rapie à base de platine pour Bruzzone [1] et de carboplatine pour Lambert [16]. L'essai de Bruzzone a é té arrê té pré maturé ment du fait d'une diffé rence significative en faveur du bras polychimiothé rapie (p = 0,02) : 9 dé cès sur 20 dans le bras RAP, et 3 dé cè s sur 21 dans le O N C O L O G I E bras chimiothé rapie.…”